First Brands Group debt targeted by Apollo Global Management - report
Investing.com -- Amarin Corporation PLC (NASDAQ:AMRN) stock rose 3.1% in premarket trading after the company presented in vitro data at the European Society of Cardiology Congress 2025 highlighting potential anti-inflammatory mechanisms of its drug VASCEPA/VAZKEPA.
The data showcased how eicosapentaenoic acid (EPA), the active ingredient in VASCEPA, may reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the NLRP3 inflammasome in monocyte-derived macrophages. The research also demonstrated EPA’s ability to inhibit lipoprotein(a) oxidation and reduce oxidative stress and pro-inflammatory protein expression in endothelial cells.
"These in vitro analyses provide additional insight into the mechanisms of action for VASCEPA/VAZKEPA, including the potential effect of reducing inflammation in atherosclerotic cardiovascular disease as well as its reported impact on reducing cardiovascular events in at-risk patients with elevated Lp(a)," said Steven Ketchum, EVP, President of R&D, and Chief Scientific Officer at Amarin .
The preliminary findings suggest EPA may reduce extracellular ATP release and caspase 1 activation in stimulated monocyte-derived macrophages from individuals with and without ASCVD, potentially protecting against inflammation by modulating the ATP-P2X7 axis.
Professor Kelvin Lee, Consultant Interventional Cardiologist and Director of the Cardiovascular Research Program at United Lincolnshire Hospitals NHS Trust, noted that the data suggests EPA’s benefits may extend beyond triglyceride lowering, potentially influencing autophagy and inflammasome activity in ways that could reduce cardiovascular risk.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.